AndreaBozzo/ceres-open-data-index huggingface dataset:
Weekly COVID-19 cases among persons ≥5 years old among unvaccinated and vaccinated with a BNT162b2 (Pfizer-BioNTech) primary series by age group — 22 U.S. jurisdictions, January 16 to May 28, 2022

Reported numbers of SARS-CoV-2 infections by age group (5–11, 12–17, 18–49, 50–64, ≥65 years of age) from 22 U.S. jurisdictions (AR, AZ, CA, CO, CT, DC, FL, GA, IN, KS, MI, MA, MN, NC, NE, NJ, NM, NYC, PHL, TN, UT, WI ); ~53% of the U.S. population) with routine linkages between COVID-19 case surveillance and immunization information system (IIS) data reported to CDC during January 16, 2022 – May 28, 2022. 
Vaccine administration (coverage) data reported to CDC were aggregated by U.S. reporting jurisdiction, MMWR week of vaccination (≥14 days after completing the primary vaccine series), FDA-approved vaccine products, and age group (5–11, 12–17, 18–49, 50–64, ≥65 years). 
Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing BNT162b2 (Pfizer-BioNTech) primary series. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. 
To estimate the number of unvaccinated persons in each MMWR week, the 2019 U.S. Census population estimates by jurisdiction and age group were used (except for California, where State Department of Finance 2021 population projections were determined to be more accurate). The number of unvaccinated persons each MMWR week was estimated by subtracting the cumulative number of vaccinated (all products) and partially vaccinated persons (all products) from the respective population totals for each jurisdiction and age group. 
Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent rates from growing unrealistically large due to potential overestimates of vaccination coverage.
Child Welfare Outcomes 2015: Report to Congress

This report to Congress provides information on the performance of states on seven national outcome categories and also includes data on contextual factors and findings of analyses conducted across states.

(PDF)

(PDF (PDF) - 2.52MB)

(PDF)

(PDF (PDF) - 354.85KB)

The PDF is best viewed in Chrome or Firefox. If using Internet Explorer (IE), please right click the link, save the file, and view it locally.

Executive Summary

Contextual FactorsState Performance on Outcome MeasuresConclusion and Recommendations for Further InvestigationChild Welfare Outcomes Data Site

Introduction to the Child Welfare Outcomes, Data, and Analysis

Outcome MeasuresContext DataData SourcesData Analyses in the Child Welfare Outcomes ReportOverview of Results and Trends in Child Welfare Outcomes 2015 Report to CongressThe Child Welfare Outcomes Report Data Site

Chapter 1: Child Welfare Outcomes Demographic Data

National Child PopulationChildren in Foster CareFoster Care Entry RatesChildren Waiting for Adoption and Children AdoptedSummary

Chapter 2: Keeping Children Safe

Child Victims and Child FatalitiesRange of State Performance in 2015 on Safety-Related Outcome MeasuresChanges Over Time in State Performance on Measures of Maltreatment Recurrence and Maltreatment of Children in Foster CareSummary of Findings Regarding Keeping Children Safe

Chapter 3: Finding Permanent Homes for Children in Foster Care

Range of Performance in Achieving Permanency for Children in Foster CareChanges Over Time in State Performance on Measures of Achieving PermanencySummary of Findings Regarding Achieving Permanency for Children in Foster Care

Chapter 4: Achieving Timely Reunifications and Adoptions for Children in Foster Care

Caseworker VisitsTimeliness of ReunificationsChanges Over Time in State Performance With Regard to Achieving Timely ReunificationsTimeliness of AdoptionsChanges Over Time in State Performance With Regard to Timeliness of AdoptionsSummary of Findings Regarding Achieving Reunifications and Adoptions in a Timely Manner

Chapter 5: Achieving Stable and Appropriate Placement Settings for Children in Foster Care

Changes Over Time in State Performance on Measures of Achieving Stable and Appropriate Placement Settings for Children in Foster CareSummary of Findings Regarding Achieving Stable and Appropriate Placements for Children in Foster Care

Chapter 6: State Comments on Performance Relevant to the Seven National Child Welfare Outcomes

Appendix A: Adoption and Safe Families Act of 1997 (Pub. L. 105—89)

Appendix B: Child Welfare Outcomes Report: Outcomes and Measures

Appendix C: Caseworker Visits

Appendix D: Child Welfare Outcomes Report: Data Sources and Elements

Appendix E: Child Maltreatment 2015: Summary of Key Findings

Appendix F: The AFCARS Report: FY 2015 Estimates

Metadata-only record linking to the original dataset. Open original dataset below.
Hospital competition, resource allocation and quality of care

Background
          A variety of approaches have been used to contain escalating hospital costs. One approach is intensifying price competition. The increase in price based competition, which changes the incentives hospitals face, coupled with the fact that consumers can more easily evaluate the quality of hotel services compared with the quality of clinical care, may lead hospitals to allocate more resources into hotel rather than clinical services.
        
        
          Methods
          To test this hypothesis we studied hospitals in California in 1982 and 1989, comparing resource allocations prior to and following selective contracting, a period during which the focus of competition changed from quality to price. We estimated the relationship between clinical outcomes, measured as risk-adjusted-mortality rates, and resources.
        
        
          Results
          In 1989, higher competition was associated with lower clinical expenditures levels compared with 1982. The trend was stronger for non-profit hospitals. Lower clinical resource use was associated with worse risk adjusted mortality outcomes.
        
        
          Conclusions
          This study raises concerns that cost reductions may be associated with increased mortality.
Treatment Episode Data Set (TEDS): 2020 Admissions To And Discharges From Publicly Funded Substance Use Treatment Facilities

This report presents national- and state-level data from the Treatment Episode Data Set (TEDS) for admissions and discharges occurring in 2020, and trend data from 2010 to 2021. It summarizes demographic information and the characteristics and outcomes of treatment for alcohol and/or drug use among clients aged 12 years and older in facilities that report to individual state administrative data systems. Data include records for treatment admissions and discharges that were received and processed through November 22, 2021.
Compound 528758: Dec-8-en-4,6-diynyl 3-methylbutanoate

Chemical compound data from PubChem database. IUPAC Name: dec-8-en-4,6-diynyl 3-methylbutanoate. Molecular Formula: C15H20O2. Molecular Weight: 232.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527021: N-Isobutanoyl 4'-fluoro fentanyl

Chemical compound data from PubChem database. IUPAC Name: N-(1-benzylpiperidin-4-yl)-N-(4-fluorophenyl)-2-methylpropanamide. Molecular Formula: C22H27FN2O. Molecular Weight: 354.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Elk Creek Seismic Waveforms 2011 (Part 11 of 19)

Coal bursts (damaging seismic events in underground coal mines) pose a substantial threat to operations and mine workers. The underground coal mines in Colorado’s North Fork Valley (NFV) have experienced many coal bursts, often with distinct characteristics from those of other US coal mining regions. To better understand these events and manage their associated risks, the National Institute for Occupational Safety and Health undertook a long-term monitoring campaign at the Elk Creek Mine in the NFV. The monitoring efforts included a seismic network composed of both surface and underground sensors, borehole pressure cells (BPCs), instrumented support Cans, convergence monitors, ground condition surveys, and several other data sources. This dataset consists of the event waveform files from the seismic network for the 983,379 events that were detected during the monitoring campaign. The waveforms are stored in HDF5 files that are broken up by week. Within the HDF5 files, the data are organized by station id, event time, and channel. The amplitudes are velocity in meters/second.
 
This is download 19 of 48 and corresponds to the time range between May 2, 2011, and May 16, 2011.
Child Welfare Outcomes 2018: Report to Congress

This report to Congress provides information on the performance of states on seven national outcome categories and also includes data on contextual factors and findings of analyses conducted across states.

(PDF (PDF) - 4,518 KB)

(PDF (PDF) - 945 KB)

The PDF is best viewed in Chrome or Firefox. If using Internet Explorer (IE), please right click the link, save the file, and view it locally.

Executive Summary

Contextual Factors

State Performance on Outcome Measures

Conclusion and Recommendations for Further Investigation

Child Welfare Outcomes Data Site

Introduction to the Child Welfare Outcomes, Data, and Analysis

Outcome Measures

Context Data

Data Sources

Data Analyses in the Report

The Child Welfare Outcomes Report Data Site

Chapter 1: Child Welfare Outcomes Demographic Data

National Child Population

Children in Foster Care

Foster Care Entry Rates

Children Waiting for Adoption and Children Adopted

Summary

Chapter 2: Keeping Children Safe

Child Victims and Child Fatalities

Range of State Performance on Safety-Related Outcome Measures

Changes Over Time in State Performance on Measures of Maltreatment Recurrence and Maltreatment of Children in Foster Care

Summary of Findings Regarding Keeping Children Safe

Chapter 3: Finding Permanent Homes for Children in Foster Care

Range of Performance in Achieving Permanency for Children in Foster Care

Changes Over Time in State Performance on Measures of Achieving Permanency

Summary of Findings Regarding Achieving Permanency for Children in Foster Care

Chapter 4: Achieving Timely Reunifications and Adoptions for Children in Foster Care

Caseworker Visits

Timeliness of Reunifications

Changes Over Time in State Performance With Regard to Achieving Timely Reunifications

Timeliness of Adoptions

Changes Over Time in State Performance With Regard to Timeliness of Adoptions

Summary of Findings Regarding Achieving Reunifications and Adoptions in a Timely Manner

Chapter 5: Achieving Stable and Appropriate Placement Settings for Children in Foster Care

Changes Over Time in State Performance on Measures of Achieving Stable and Appropriate Placement Settings for Children in Foster Care

Summary of Findings Regarding Achieving Stable and Appropriate Placements for Children in Foster Care

Chapter 6: State Comments on Performance Relevant to the Seven National Child Welfare Outcomes

Appendix A: Adoption and Safe Families Act of 1997 (Pub. L. 105—89)

Appendix B: Child Welfare Outcomes Report: Outcomes and Measures

Appendix C: Caseworker Visits

Appendix D: Child Welfare Outcomes Report: Data Sources and Elements

Appendix E: Child Maltreatment 2018: Summary of Key Findings

Appendix F: The AFCARS Report: FY 2018 Estimates

Appendix G: Data-Quality Criteria

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 526843: 8-Hydroxy-palmitic acid, methyl ester, tBDMS ether

Chemical compound data from PubChem database. IUPAC Name: methyl 8-[tert-butyl(dimethyl)silyl]oxyhexadecanoate. Molecular Formula: C23H48O3Si. Molecular Weight: 400.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
HHS Unaccompanied Children Program

This data is no longer being updated. New data is being tracked at https://healthdata.gov/National/HHS-Unaccompanied-Children-Program/ehpz-xc9n

This data represents unaccompanied children who are taken into custody by Customs and Border Protection brought to a facility and processed for transfer to the Department of Health and Human Services (HHS) as required by law. HHS holds the child for testing and quarantine, and shelters the child until the child is placed with a sponsor here in the United States.
Compound 526274: 1,3,6,8-Tetrabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 1,3,6,8-tetrabromodibenzofuran. Molecular Formula: C12H4Br4O. Molecular Weight: 483.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529898: 3-(4-Hydroxy-3,5-dimethoxyphenyl)propanal

Chemical compound data from PubChem database. IUPAC Name: 3-(4-hydroxy-3,5-dimethoxyphenyl)propanal. Molecular Formula: C11H14O4. Molecular Weight: 210.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528381: 2,5-Dichloro-4-hydroxybenzaldehyde

Chemical compound data from PubChem database. IUPAC Name: 2,5-dichloro-4-hydroxybenzaldehyde. Molecular Formula: C7H4Cl2O2. Molecular Weight: 191.01. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528077: Quinoline, 8-methyl-5-(1-methylethyl)

Chemical compound data from PubChem database. IUPAC Name: 8-methyl-5-propan-2-ylquinoline. Molecular Formula: C13H15N. Molecular Weight: 185.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
COVID-19 State Profile Report - California

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Compound 528810: Benzyl 4-[(trimethylsilyl)oxy]benzoate

Chemical compound data from PubChem database. IUPAC Name: benzyl 4-trimethylsilyloxybenzoate. Molecular Formula: C17H20O3Si. Molecular Weight: 300.42. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399588-T1: [Translated] METHOD FOR DRYING COMPRESSED GAS AND DEVICE USED

Method for drying the compressed gas of a compressor device (1) having at least two pressure stages (4-5), whereby a dryer (3) is used with at least two pressure vessels (9-12) which are filled with a desiccant and which work alternately, such that when one pressure vessel (12) is in action to dry the compressed gas, the other pressure vessel (9) is being regenerated, whereby, in order to regenerate the other pressure vessel (9), at least a part of this compressed gas is guided through the regenerating pressure vessel (9), and at least at the end of the regeneration cycle, this part of the compressed gas, after its passage through the regenerating pressure vessel, is guided to the pressure pipe (6) between two pressure stages (4-5).
Emtricitabine and tenofovir disoproxil fumarate

Emtricitabine and Tenofovir Disoproxil Fumarate is a generic prescription tablet combining two antiviral medications to treat HIV infection by blocking the virus from multiplying in the body. Each tablet contains 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate, taken orally once daily. Manufactured by Aurobindo Pharma Limited, it's approved as an ANDA drug. This information was generated using AI and is provided for informational and research purposes only.
Analysis of fluorescently labeled substance P analogs: binding, imaging and receptor activation

Background
          Substance P (SP) is a peptide neurotransmitter found in central and peripheral nerves. SP is involved in the control of smooth muscle, inflammation and nociception. The amino acid sequence of SP is Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2. Five different forms of fluorescently labeled SP have recently been synthesized, in which Alexa 488, BODIPY Fl, fluorescein, Oregon Green 488 or tetramethylrhodamine has been covalently linked to SP at Lys3. Here, these novel analogs are characterized as to their ligand binding, receptor activation and fluorescence labeling properties.
        
        
          Results
          Competition binding studies, using radiolabeled [125I] SP, revealed that all of the labeled forms of SP, except for Alexa 488-SP, effectively competed with radiolabeled SP for binding at the rat SP receptor. With the exception of Alexa 488-SP, all of the SP analogs produced Ca++ elevations and fluorescence labeling of the SP receptor expressed in Chinese hamster ovary cells. In SP-responsive neurons, BODIPY Fl-SP and Oregon Green 488-SP were as effective as unlabeled SP in producing a reduction of the M-type K+ current. Fluorescein-SP produced variable results, while tetramethylrhodamine-SP was less potent and Alexa 488-SP was less effective on intact neurons.
        
        
          Conclusions
          The above results show that fluorescent labeling of SP altered the biological activity and the binding properties of the parent peptide. Oregon Green 488 and BODIPY FL-SP are the most useful fluorophores for labeling SP without affecting its biological activity. Given these results, these probes can now be utilized in further investigations of the mechanisms of SPR function, including receptor localization, internalization and recycling.
Compound 529952: 2-Oxo-3-pentyl 3-oxo-2-butyl disulfide

Chemical compound data from PubChem database. IUPAC Name: 3-(3-oxobutan-2-yldisulfanyl)pentan-2-one. Molecular Formula: C9H16O2S2. Molecular Weight: 220.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Abrocitinib

Cibinqo (abrocitinib) is an oral prescription medication manufactured by Pfizer, classified as a Janus Kinase inhibitor. It's used to treat moderate-to-severe atopic dermatitis (eczema) in adults and adolescents. Available in tablet form with strengths of 50mg, 100mg, and 200mg. This information was generated using AI and is provided for informational and research purposes only.
Granisetron hydrochloride

Granisetron Hydrochloride is an injectable prescription medication used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, or surgery. It works by blocking serotonin receptors in the body. Administered intravenously by healthcare professionals, each milliliter contains 1 mg of the active ingredient. Manufactured by Fresenius Kabi USA, LLC. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E400219-T1: [Translated] METHOD FOR QUANTIFYING HUMAN ALERT

Chemical patent from PubChem database. Patent Number: AT-E400219-T1. Title: Pharmaceutical Formulation and Method of Use. Filing Date: 1998-12-05. Inventors: Chen, Wei, Kumar, Raj, Williams, Sarah. Abstract: The invention relates to pharmaceutical formulations containing active ingredients and methods for their therapeutic use in treating various medical c... IPC Classifications: A61K, A61P, C07D. This patent covers 33 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 528014: 4-Pentenyl 4-nitrobenzoate

Chemical compound data from PubChem database. IUPAC Name: pent-4-enyl 4-nitrobenzoate. Molecular Formula: C12H13NO4. Molecular Weight: 235.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
High-resolution physical map for chromosome 16q12.1-q13, the Blau syndrome locus

Background
          The Blau syndrome (MIM 186580), an autosomal dominant granulomatous disease, was previously mapped to chromosome 16p12-q21. However, inconsistent physical maps of the region and consequently an unknown order of microsatellite markers, hampered us from further refining the genetic locus for the Blau syndrome. To address this problem, we constructed our own high-resolution physical map for the Blau susceptibility region.
        
        
          Results
          We generated a high-resolution physical map that provides more than 90% coverage of a refined Blau susceptibility region. The map consists of four contigs of sequence tagged site-based bacterial artificial chromosomes with a total of 124 bacterial artificial chromosomes, and spans approximately 7.5 Mbp; however, three gaps still exist in this map with sizes of 425, 530 and 375 kbp, respectively, estimated from radiation hybrid mapping.
        
        
          Conclusions
          Our high-resolution map will assist genetic studies of loci in the interval from D16S3080, near D16S409, and D16S408 (16q12.1 to 16q13).